Stableford Capital II LLC Lowers Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Stableford Capital II LLC decreased its holdings in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 40.7% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 9,321 shares of the company's stock after selling 6,409 shares during the period. Stableford Capital II LLC's holdings in Johnson & Johnson were worth $1,468,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently added to or reduced their stakes in JNJ. WealthTrak Capital Management LLC acquired a new position in shares of Johnson & Johnson during the 4th quarter worth about $26,000. Mountain Hill Investment Partners Corp. acquired a new position in Johnson & Johnson in the 4th quarter valued at $29,000. Conquis Financial LLC acquired a new stake in Johnson & Johnson during the 4th quarter worth $33,000. Bernard Wealth Management Corp. purchased a new stake in shares of Johnson & Johnson during the fourth quarter worth $36,000. Finally, Runnymede Capital Advisors Inc. acquired a new stake in shares of Johnson & Johnson in the fourth quarter valued at about $38,000. Institutional investors and hedge funds own 69.55% of the company's stock.

Johnson & Johnson Stock Down 0.6%

Shares of JNJ stock traded down $0.92 during trading hours on Friday, reaching $149.81. 22,591,152 shares of the stock were exchanged, compared to its average volume of 7,993,824. The business's fifty day moving average is $154.07 and its two-hundred day moving average is $153.65. The firm has a market capitalization of $360.44 billion, a P/E ratio of 16.66, a P/E/G ratio of 2.27 and a beta of 0.42. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $169.99. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.26 and a quick ratio of 1.03.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings data on Tuesday, April 15th. The company reported $2.77 EPS for the quarter, beating analysts' consensus estimates of $2.59 by $0.18. The company had revenue of $21.89 billion for the quarter, compared to the consensus estimate of $21.65 billion. Johnson & Johnson had a net margin of 24.42% and a return on equity of 33.46%. As a group, research analysts expect that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, June 10th. Stockholders of record on Tuesday, May 27th were issued a $1.30 dividend. This is a boost from Johnson & Johnson's previous quarterly dividend of $1.24. The ex-dividend date was Tuesday, May 27th. This represents a $5.20 annualized dividend and a dividend yield of 3.47%. Johnson & Johnson's dividend payout ratio is presently 57.84%.

Wall Street Analysts Forecast Growth

A number of research firms have commented on JNJ. Wall Street Zen upgraded shares of Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a report on Saturday. Leerink Partnrs cut Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a report on Tuesday, May 13th. Leerink Partners downgraded Johnson & Johnson from an "outperform" rating to a "market perform" rating and reduced their price objective for the stock from $169.00 to $153.00 in a research report on Tuesday, May 13th. Raymond James Financial dropped their target price on Johnson & Johnson from $165.00 to $162.00 and set an "outperform" rating for the company in a report on Monday, April 14th. Finally, Benchmark upgraded Johnson & Johnson to a "strong-buy" rating in a report on Thursday, April 24th. Eleven equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and three have given a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $170.88.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.